AB0460 Glpg0634, A Selective JAK1 Inhibitor, Confirms Its Low Liability for Drug-Drug Interactions (original) (raw)
THU0017 IN Vitro Mechanistic Studies Demonstrate Filgotinib Activity That Has Potential Implications for Differentiation Among Jak Inhibitors
Nevena Mollova
Poster Presentations, 2019
View PDFchevron_right
Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials
Gerben A E van 't Klooster
Arthritis & Rheumatology
View PDFchevron_right
A Comprehensive Overview of Globally Approved JAK Inhibitors
Ahmed Shawky, Faisal Almalki
View PDFchevron_right
Selective JAK inhibitors
Joy, Yu-Yi Chu
View PDFchevron_right
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2)
Mykola Stanislavchuk
Annals of the Rheumatic Diseases, 2016
View PDFchevron_right
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
Federico Campigotto
Annals of the Rheumatic Diseases, 2021
View PDFchevron_right
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
Lubomir Sokol
Leukemia Research, 2014
View PDFchevron_right
DMD #033787 -1 - Metabolism, Excretion and Pharmacokinetics of 14 C-INCB018424, a Selective JAK1/2 Inhibitor, in Humans DMD #033787 -2 - Running Title Page Running title: INCB018424 Metabolism, Excretion and Pharmacokinetics in Humans
Naresh Punwani
2020
View PDFchevron_right
P460 Evaluation of potential mechanisms underlying the safety observations of filgotinib in clinical studies in rheumatoid arthritis
Nevena Mollova
Journal of Crohn's and Colitis, 2020
View PDFchevron_right
The specificity of JAK3 kinase inhibitors
David Perregaux
Blood, 2008
View PDFchevron_right
In-Silico Approach for Identification of The Most Potent JAK Inhibitors as a Possible Treatment for Myelofibrosis
Arli Parikesit
Chemrxiv, 2023
View PDFchevron_right
Preclinical Characterization of GLPG0634, a Selective Inhibitor of JAK1, for the Treatment of Inflammatory Diseases
R. Galien, E. van der Aar, Gerben A E van 't Klooster, Steve De Vos, Katja Conrath
The Journal of Immunology, 2013
View PDFchevron_right
Tricyclic Covalent Inhibitors Selectively Target Jak3 through an Active Site Thiol
jonathan george
Journal of Biological Chemistry, 2014
View PDFchevron_right
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Amina H
Blood, 2011
View PDFchevron_right
In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2
Kausar Ahmed
Experimental Hematology, 2011
View PDFchevron_right
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors
Gauri Deshmukh
Bioorganic & Medicinal Chemistry Letters, 2013
View PDFchevron_right
Structure-Function Correlation of G6, a Novel Small Molecule Inhibitor of Jak2
Tímea Polgár
Journal of Biological Chemistry, 2010
View PDFchevron_right
and nilotinib Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib
Nicolas Widmer
2013
View PDFchevron_right
The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious JAK1 Selective Inhibitor with Favorable Pharmacokinetic Properties
Lauren Dorosh
Journal of medicinal chemistry, 2017
View PDFchevron_right
The design of a Janus Kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans
Mai Shihah binti Haji Abdullah abdullah
Journal of medicinal chemistry, 2017
View PDFchevron_right
Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
José Trigo
Clinical and Translational Oncology, 2012
View PDFchevron_right
JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders
Caroline Marty
F1000Research
View PDFchevron_right
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Przemyslaw Kotyla
International Journal of Molecular Sciences
View PDFchevron_right
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
Paul Changelian
Current Opinion in Pharmacology, 2012
View PDFchevron_right
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Suguru Honda
Drugs
View PDFchevron_right
Pharmacophore and Virtual Screening of JAK3 inhibitors
Santhi Natchimuthu
Bioinformation, 2014
View PDFchevron_right
Inside Perspective of the Synthetic and Computational Toolbox of JAK Inhibitors: Recent Updates
Antonio Lupia
Molecules
View PDFchevron_right
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
Glenn Noronha
Leukemia, 2007
View PDFchevron_right
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
neil wishart
BMC Rheumatology
View PDFchevron_right
Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors
Pascal Furet
Bioorganic & Medicinal Chemistry Letters, 2010
View PDFchevron_right
JAK2 impact on response to anagrelide
Dove Medical Press, Alessandro Vannucchi
2015
View PDFchevron_right